HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beiersdorf

This article was originally published in The Rose Sheet

Executive Summary

Company unveils supply chain realignment plan Nov. 22. Three-year initiative aims to "optimize" firm's international supply chain, including purchasing, production, distribution and delivery, and help Beiersdorf "introduce innovations better, faster and more efficiently to further strengthen the company's position in an increasingly competitive market," according to the company. Beiersdorf will "create a seamless, global supply chain network, in which all production and logistics processes are managed centrally." Firm additionally will seek to "make its production and logistics network more efficient and adjust capacities in Europe" by reducing production, warehouse locations and headcount in the region. Company anticipates resulting cost savings of about €100 mil. per year. From 2006 to 2008, however, the firm said it expects to record one-time charges of about €220 mil...

You may also be interested in...



Beiersdorf

Company's 85 employees from wound care factory in Hamburg/Hausbruch "will be offered a comparable job in the production of skin care products in Hamburg/Eimsbüttel" under previously announced supply chain reorganization, firm says. Initiative, which was unveiled in November, is intended to optimize firm's international supply chain, including purchasing, production, distribution and delivery, and help Beiersdorf "introduce innovations better, faster and more efficiently to further strengthen the company's position in an increasingly competitive market," according to the firm (1"The Rose Sheet" Nov. 28, 2005, In Brief). Reorganization is expected to generate annual cost savings of €100 mil...

Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.

MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation

Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013527

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel